Dr. Rachel Kaye Voss, MD

Dr. Voss practices at H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida.

Dr. Voss' NPI, 1194075861, was assigned on September 10, 2012. Dr. Voss graduated from Ohio State College of Medicine in 2012. Dr. Voss holds Florida license ME150959.

Dr. Voss' primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD, at 10901 McKinley Dr, Tampa, FL 33612.

Dr. Voss' primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida. Dr. Voss is also affiliated with Moffitt Cancer Hospital. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Voss to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Voss practices, 3 sites in all. Vendor and product names are available with a free account.

Surgery is Dr. Voss' primary specialty in the NPI Registry, under taxonomy code 208600000X. Dmand AI has Dr. Voss' licenses on file in 2 states: Florida and Texas.

Dmand AI lists cancerous skin growth removal, colon removal, esophagus, stomach, or upper small intestine surgery and removal of damaged skin or skin graft among the conditions Dr. Voss treats.

CMS data shows 80 Medicare services from Dr. Voss across 3 procedure codes in 2024, all of them office visits, for 85 Medicare patients. Medicare paid $8,253 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 85 Medicare patients who saw Dr. Voss in 2024. The largest group is 65 to 74, with 42 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.72, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Voss' median patient age at 67, with 53% women.

In 2024, Dr. Voss wrote 39 Medicare Part D claims for 19 patients. 92% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $157 in total drug cost. In 2020, CMS named 14 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Voss for performance year 2024, reported as part of a group. Dr. Voss accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Voss as offering telehealth.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 12 papers to Dr. Voss, published from 2015 to 2023. 2021 was the busiest year, with 2. The most frequent topics are Sarcoma, Gastrointestinal Stromal Tumors and Imatinib Mesylate. Dr. Voss has published most often in Ann Surg Oncol. Dr. Voss' most frequent co-authors are Christina Lynn Roland, MD, Janice N. Cormier, MD, MPH and Barry W. Feig, MD.

CMS Open Payments shows 8 general payments to Dr. Voss from 5 drug and device companies from 2016 to 2025. Travel and lodging make up the largest share, 56% of the total. Stryker Corporation paid the most, $663.

Dr. Voss graduated from Ohio State College of Medicine in 2012.

Dr. Voss is in network with 6 carriers, including Excellus BlueCross BlueShield, United Healthcare and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 5. Check the plan with the practice before a visit.